Global Anti Obesity Drugs Market

Anti Obesity Drugs Market Size, Share, Growth Analysis, By Type(Prescription Drugs, OTC Drugs), By Distribution channel(Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), By Region - Industry Forecast 2024-2031


Report ID: SQMIG35D2060 | Region: Global | Published Date: April, 2024
Pages: 165 | Tables: 62 | Figures: 75

Anti Obesity Drugs Market Dynamics

Anti Obesity Drugs Market Driver

  • Growing worries about appropriate management of obesity have been sparked by the population's significant increase in sufferers. For instance, the World Obesity Federation estimates that 650 million people and 120 million children worldwide are obese at the moment. Additionally, it costs about US$ 2 trillion yearly to manage obesity. Additionally, according to the Centers for Disease Control and Prevention (CDC), 42.5% of US individuals aged 20 and older are obese. The demand for anti-obesity medications is expected to rise during the forecast period due to patients' increased knowledge of the importance of managing weight gain promptly in emerging economies.

Anti Obesity Drugs Market Restraint 

  • The prevalence of obesity is rising internationally, yet treatment rates for the illness are still low due to inadequate education about weight control and erroneous public perceptions. Only 2% of the whole obese population is treated with prescription drugs, according to our study. This is mostly to blame for the reduced drug acceptance, which would hinder market expansion. Another factor limiting the market's growth is the presence of a small number of major players who concentrate on the development of treatments for obesity, as well as the negative effects of these medications.
$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Anti Obesity Drugs Market size was valued at USD 1.9 billion in 2019 and is poised to grow from USD 2.82 billion in 2023 to USD 13.26 billion by 2031, growing at a CAGR of 24.6% in the forecast period (2024-2031).

The top players are concentrated on inorganic expansion tactics such as teaming up with successful individuals and national initiatives or programmes that advertise their goods. As a result, these brands are known earlier than other brands in the industry under investigation. Due to the disease's great prevalence, there is moderate to intense intergroup conflict. 'Novo Nordisk A/S', 'Eisai Co., Ltd.', 'Arena Pharmaceuticals, Inc.', 'F. Hoffmann-La Roche Ltd.', 'Orexigen Therapeutics, Inc.', 'Takeda Pharmaceutical Company Limited', 'Zafgen, Inc.', 'Norgine B.V.', 'GlaxoSmithKline plc', 'Boehringer Ingelheim International GmbH', 'Pfizer Inc.', 'Sanofi S.A.', 'Merck & Co., Inc.', 'VIVUS, Inc.', 'Johnson & Johnson', 'Teva Pharmaceutical Industries Ltd.', 'Bristol-Myers Squibb Company', 'Abbott Laboratories', 'AstraZeneca plc', 'Bayer AG'

Growing worries about appropriate management of obesity have been sparked by the population's significant increase in sufferers. For instance, the World Obesity Federation estimates that 650 million people and 120 million children worldwide are obese at the moment. Additionally, it costs about US$ 2 trillion yearly to manage obesity. Additionally, according to the Centers for Disease Control and Prevention (CDC), 42.5% of US individuals aged 20 and older are obese. The demand for anti-obesity medications is expected to rise during the forecast period due to patients' increased knowledge of the importance of managing weight gain promptly in emerging economies.

The development of various possible therapeutic compounds that target both Type 2 diabetes mellitus and obesity has also become a major trend among companies competing in the anti-obesity industry. The rising prevalence of Type 2 diabetes and obesity is motivating manufacturers and researchers to develop medications that can treat both conditions. Therefore, it is anticipated that the rise in unhealthy eating patterns, sedentary lifestyles, and the obese population will propel market expansion throughout the forecast period.

The North American market has a value of US$ 964.8 million. This region’s dominance can be attributed to the US's strong players and the rising popularity of obesity control products. Due to its efforts in R&D for the creation of therapeutically effective medications, Europe currently occupies the second-place position in the market. Growth is anticipated during the projection period as a result of this as well as rising public awareness of the advantages of weight loss.

Anti Obesity Drugs Market size was valued at USD 1.9 billion in 2021 and is poised to grow from USD 2.82 billion in 2022 to USD 13.26 billion by 2030, growing at a CAGR of 24.6% in the forecast period (2023-2030).

The top players are concentrated on inorganic expansion tactics such as teaming up with successful individuals and national initiatives or programmes that advertise their goods. As a result, these brands are known earlier than other brands in the industry under investigation. Due to the disease's great prevalence, there is moderate to intense intergroup conflict. 'Novo Nordisk A/S', 'Eisai Co., Ltd.', 'Arena Pharmaceuticals, Inc.', 'F. Hoffmann-La Roche Ltd.', 'Orexigen Therapeutics, Inc.', 'Takeda Pharmaceutical Company Limited', 'Zafgen, Inc.', 'Norgine B.V.', 'GlaxoSmithKline plc', 'Boehringer Ingelheim International GmbH', 'Pfizer Inc.', 'Sanofi S.A.', 'Merck & Co., Inc.', 'VIVUS, Inc.', 'Johnson & Johnson', 'Teva Pharmaceutical Industries Ltd.', 'Bristol-Myers Squibb Company', 'Abbott Laboratories', 'AstraZeneca plc', 'Bayer AG'

Growing worries about appropriate management of obesity have been sparked by the population's significant increase in sufferers. For instance, the World Obesity Federation estimates that 650 million people and 120 million children worldwide are obese at the moment. Additionally, it costs about US$ 2 trillion yearly to manage obesity. Additionally, according to the Centers for Disease Control and Prevention (CDC), 42.5% of US individuals aged 20 and older are obese. The demand for anti-obesity medications is expected to rise during the forecast period due to patients' increased knowledge of the importance of managing weight gain promptly in emerging economies.

The development of various possible therapeutic compounds that target both Type 2 diabetes mellitus and obesity has also become a major trend among companies competing in the anti-obesity industry. The rising prevalence of Type 2 diabetes and obesity is motivating manufacturers and researchers to develop medications that can treat both conditions. Therefore, it is anticipated that the rise in unhealthy eating patterns, sedentary lifestyles, and the obese population will propel market expansion throughout the forecast period.

The North American market has a value of US$ 964.8 million. This region’s dominance can be attributed to the US's strong players and the rising popularity of obesity control products. Due to its efforts in R&D for the creation of therapeutically effective medications, Europe currently occupies the second-place position in the market. Growth is anticipated during the projection period as a result of this as well as rising public awareness of the advantages of weight loss.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Anti Obesity Drugs Market

Report ID: SQMIG35D2060

$5,300
BUY NOW GET FREE SAMPLE